|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
Clinuvel Pharmaceuticals (CUV.AX)
Trading: HOLD @ $36.49
Signal Strength: MEDIUM
Clinuvel Pharmaceuticals (ASX:CUV) currently has positive momentum of 2.81. This means the current price is greater than the price 14 days ago and therefore gaining momentum.
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has the ability to detect the speed of movement & give an early signal for a potential movement. By understanding the rate at which the price is moving in respect to the stocks historical trades, enables positions to be set in place based on changes in the speed of movement
Momentum measures the rate of change in closing prices and is used to detect trend weakness and likely reversal points. It is often underrated because of its simplicity. High Momentum readings (positive or negative) occur when a trend is at its strongest. Lower readings are found at the start and end of trends. Overbought and oversold levels are set separately for each security based on the performance of the indicator over past cycles.
Calculation: Momentum Oscillator (MOM):
1) Closing Price [today] - Closing Price [n days ago];
PROFILE: Clinuvel Pharmaceuticals (CUV.AX)
Stock Exchange: ASX
Company: Clinuvel Pharmaceuticals
Ticker Codes: | CUV.AX | ASX:CUV |
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of a range of severe skin disorders. Its lead drug compound is SCENESSE, a medicinal photoprotective and repigmentation drug that has completed Phase II and III trials in the United States and Europe, which is used for the prevention of phototoxicity in adults with erythropoietic protoporphyria. The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue that acts as a potent skin protectant; and VLRX001, an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity. It has operations in Europe, the United States, and Singapore. The company is headquartered in Melbourne, Australia.
|BRN Brainchip Holdings||0.08||11.6||9,040,170||0.03||BULLISH|
|SLR Silver Lake Resources||0.94||8.7||10,759,307||0.14||BULLISH|
|RAP Resapp Health||0.2||8.3||2,913,547||0.05||BULLISH|
|OMH OM Holdings||0.92||5.8||56,591||0.15||BULLISH|
|IRI Integrated Research||3.15||5||286,098||0.43||BULLISH|
|CWY Cleanaway Waste Management||2.37||4.9||5,497,121||0.13||BULLISH|
|PRU Perseus Mining||0.52||4||9,497,712||0.05||BULLISH|